Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
Johnson & Johnson to collaborate with Apple to assess impact of wearable technology on earlier detection of AFib, improved diagnosis and patient outcomesUp to 30 percent of AFib cases go undiagnosed until life-threatening complications occur, signaling a critical need for more efficient and scalable screening methods
NEW BRUNSWICK, N.J.,? Johnson & Johnson?(NYSE: JNJ) today announced that?Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with?Apple Inc.?to investigate whether a new heart health program using an app from?Johnson & Johnson?in combination with Apple Watch's irregular rhythm notifications and ECG app can accelerate the diagnosis and improve health outcomes of the 33 million people worldwide living with atrial fibrillation (AFib),?a condition that can lead to stroke and other potentially?devastating complications. In the U.S. alone, AFib?is responsible for approximately 130,000 deaths and 750,000 hospitalizations every year.[i]
The study aims to analyze the impact of Apple Watch on the early detection and diagnosis of?AFib, and the potential to improve outcomes including the prevention of stroke. A multi-year research program will be launched later in 2019. This large-scale program will occur in the U.S. only, and will be designed as a pragmatic randomized controlled research study for individuals age 65 years or older.
The study's goals include:
- Measuring the outcomes of a heart health engagement program with irregular rhythm notifications on?Apple Watch.
- Assessing the impact of a medication adherence program using an app from?Johnson & Johnson.
?View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-announces-research-study-with-apple-watch-to-help-improve-afib-outcomes-including-stroke-prevention-300780002.html
SOURCE?Johnson & Johnson Press Contact: Ernie Knewitz, (732) 524-6623, (917) 697-2318 (M); Investor Relations: Lesley Fishman, (732) 524-3922; Margo, T: 732-524-3541, M: 732-266-6495, Email: mdavis21@its.jnj.com